HAL (France)open access
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Phase III as topic, Combination, Non-small cell lung cancer, Programmed cell death 1 receptor, Drug therapy, 0, Immunotherapy, Clinical trials
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 262149
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.